Targeting the RAS-RAF-MEK-ERK pathway using BRAF, MEK, and ERK inhibitors improves the resistance to EGFR-targeting therapy in KRAS/BRAF-mutant CRC cells [8]. This evidence concerns the gene EGFR and colorectal carcinoma.